phase 1
The Clinical Trials Guru's Dan Sfera on Innovation in Phase 1 Studies and Beyond
July 30 by Andrea CharlesIt’s no secret that pharma and bio are struggling to fill their pipelines. Dan Sfera from The Clinical Trials Guru, joins Andrea Charles from Pharma IQ to discuss specific challenges ...
Troubleshooting Biomarker Development Strategies
June 09 by Gabriele DallmannIn this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical developme...
Best Practice Tips for Overcoming Obstacles in Biomarker Development
July 29 by Pharma IQHow can we overcome the latest challenges in Biomarker Development? Birgitte Søgaard, Divisional Director for Clinical Pharmacology and Translational Medicine at H Lundbeck A/S, discusses wit...
Pfizer's Future vision for Clinical Trials
March 29 by Craig LipsetThere are mounting challenges around the sustainability of clinical trials as the pharmaceutical industry is faced with increasingly complex and expensive trials. But new models and collaberat...
How to Optimise Your Biomarker Development Strategies
March 29 by Kristof VercruysseKristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH about Innovation in phase 1 clinical development and optimisation of biomarker d...